UniQure's Huntington's Disease Drug Faces FDA Roadblocks, Shares Fall 15%

UniQure shares fell 15% after the FDA said data from its Huntington's disease drug AMT-130 is unlikely to support a biologics license application. The company will request a follow-up meeting with the FDA in Q1 2026 to advance the drug. AMT-130 is being developed to slow the progression of Huntington's disease and was previously granted breakthrough-therapy designation.